Dr. Gemma Serrano is a biomedical researcher with a strong track record in molecular and clinical research. She holds a PhD in Biological Sciences from the Autonomous University of Madrid, where she trained under Dr. Margarita Salas. Since 2009, she has worked at the University Hospital of Albacete, gaining extensive experience in clinical research, biomarker analysis, and project management. She has authored 29 publications, including 8 in top-decile journals, and co-authored 14 collaborative papers in high-impact journals such as Brain, Stroke, Neurology, and Circulation Research. Her h-index is 23 (Scopus), with an average of 165 citations per year over the past five years. Dr. Serrano has supervised two PhD theses and currently co-supervises four more. She is Executive Secretary of the Research Committee at the Albacete Integrated Healthcare Management since 2017. Her research focuses on cerebrovascular diseases, neuro-oncology—including strategies to overcome temozolomide resistance and treatments for VHL-related hemangioblastomas—and post-COVID neuroinflammation. She is highly skilled in molecular biology, proteomics, cell culture, flow cytometry, and omics data analysis.